Simcere Pharmaceutical raises HK$1.55bn for R&D and strategic initiatives

Simcere Pharmaceutical Group Limited announced the completion of its placing of existing shares and top-up subscription of new shares under a general mandate. The placing, completed on September 4, 2025, involved 121,000,000 Sale Shares at HK$12.95 per share. The subsequent subscription, completed on September 10, 2025, saw the Vendor subscribe for an equal number of shares at the same price, representing approximately 4.66% of the company's enlarged issued shares.

The company successfully raised total net proceeds of approximately HK$1,553.5 million from the subscription. Simcere plans to allocate approximately 90% (HK$1,398.1 million) of these proceeds towards R&D-related expenditures, focusing on advancing clinical research for new drugs in China and the United States, and supporting new indication expansions for approved innovative drugs.

The remaining 10% (HK$155.3 million) will be used for working capital and other general corporate purposes, supporting the Group's daily operations and long-term development. Morgan Stanley acted as the Sole Overall Coordinator, Sole Global Coordinator, Sole Bookrunner, and Placing Agent for the transaction.